Drug intelligence / Profile preview

PGX-TEC

Development stage: Preclinical
Lead developer: Ceapro
Administration: Oral, Topical

Overview

PGX-TEC is a preclinical-stage asset developed by Ceapro using its proprietary Pressurized Gas eXpanded (PGX) technology. The lead candidate, PGX-TEC-Yeast Beta Glucan, is a yeast-derived beta-glucan formulated as an oral tablet intended for use as an immunity modulator. The PGX technology allows for the creation of high-surface-area biopolymers, which can be used to enhance the delivery and efficacy of bioactive ingredients. Another application in the pipeline is Loaded PGX-TEC-ALG (alginate), which is being investigated for wound healing. Beta-glucans are known to interact with immune receptors such as Dectin-1 to stimulate innate immune responses.

Other names: PGX-TEC-Yeast Beta GlucanLoaded PGX-TEC-ALG

Targets

CLEC7A (Dectin-1)

Beyond the preview

Go deeper on PGX-TEC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGX-TEC.

Explore the full profile